Journal of Clinical Gastroenterology and Hepatology Open Access

  • ISSN: 2575-7733
  • Journal h-index: 5
  • Journal CiteScore: 0.63
  • Journal Impact Factor: 0.41
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Abstract

Sarcopenia in Gastric Cancer

Leping Li*, Zhen Fang and Liang Shang

Gastric Cancer (GC) is one of the common malignant tumors. Although treatment of GC has improved, overall survival remains low. The main treatment for GC is gastrectomy. Finding the risk factors affecting the prognosis after gastrectomy and taking active treatment and intervention measures are of great significance to improve the prognosis of gastric cancer. Sarcopenia comes from the greek sarx (muscle) and penia (loss). It was first proposed by Professor Rosenberg in 1989.

The prominent feature of sarcopenia is decreased skeletal muscle mass and function. Many studies have shown that sarcopenia is closely related to the prognosis of GC patients. Many international organizations studying sarcopenia have reached consensus and established cut off points for the diagnosis of sarcopenia. Currently, sarcopenia has been officially recognized as a muscle disease with the diagnosis code: ICD-10-MC. This review discusses the research progress of sarcopenia and its relationship with GC, and looks forward to future research directions in this field.

Published Date: 2022-10-17; Received Date: 2021-03-10